Matt Miksic
Stock Analyst at Barclays
(3.72)
# 537
Out of 5,178 analysts
336
Total ratings
54.96%
Success rate
4.71%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $217 → $234 | $239.24 | -2.19% | 16 | Mar 19, 2026 | |
| COO The Cooper Companies | Maintains: Overweight | $98 → $103 | $71.54 | +43.98% | 3 | Mar 6, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $63.65 | +14.69% | 10 | Feb 27, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $86 → $90 | $74.47 | +20.85% | 11 | Feb 26, 2026 | |
| GMED Globus Medical | Maintains: Overweight | $118 → $123 | $86.50 | +42.20% | 17 | Feb 25, 2026 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $20 | $15.89 | +25.87% | 7 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Overweight | $116 → $118 | $87.67 | +34.60% | 25 | Feb 18, 2026 | |
| DXCM DexCom | Maintains: Underweight | $71 → $72 | $66.09 | +8.94% | 10 | Feb 13, 2026 | |
| BAX Baxter International | Maintains: Overweight | $30 → $25 | $16.67 | +49.97% | 24 | Feb 13, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $104 → $100 | $89.15 | +12.17% | 10 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $202 | $157.38 | +28.35% | 2 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $87 | $71.54 | +21.61% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $124 | $70.17 | +76.71% | 20 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $169 → $142 | $104.57 | +35.79% | 32 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $686 → $712 | $468.55 | +51.96% | 9 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $82.10 | +26.67% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $218.11 | +25.62% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $4.50 | +166.96% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $11.52 | +134.38% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $23.32 | +135.85% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $6.56 | +372.56% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $332.68 | +36.17% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $0.78 | +349.64% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.75 | +52.73% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.39 | +308.16% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $73.71 | +35.67% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $177.33 | +135.72% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $13.54 | +106.79% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.67 | +474.37% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $9.38 | +827.51% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.42 | +933.06% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $10.05 | +138.81% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $3.94 | +128.43% | 1 | Dec 12, 2016 |
Johnson & Johnson
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $217 → $234
Current: $239.24
Upside: -2.19%
The Cooper Companies
Mar 6, 2026
Maintains: Overweight
Price Target: $98 → $103
Current: $71.54
Upside: +43.98%
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $63.65
Upside: +14.69%
Alcon
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $74.47
Upside: +20.85%
Globus Medical
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $86.50
Upside: +42.20%
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $15.89
Upside: +25.87%
Medtronic
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $118
Current: $87.67
Upside: +34.60%
DexCom
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $66.09
Upside: +8.94%
Baxter International
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $16.67
Upside: +49.97%
Zimmer Biomet Holdings
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $89.15
Upside: +12.17%
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $157.38
Upside: +28.35%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $71.54
Upside: +21.61%
Feb 3, 2026
Maintains: Overweight
Price Target: $136 → $124
Current: $70.17
Upside: +76.71%
Feb 2, 2026
Maintains: Overweight
Price Target: $169 → $142
Current: $104.57
Upside: +35.79%
Jan 26, 2026
Maintains: Overweight
Price Target: $686 → $712
Current: $468.55
Upside: +51.96%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $82.10
Upside: +26.67%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $218.11
Upside: +25.62%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.50
Upside: +166.96%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $11.52
Upside: +134.38%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $23.32
Upside: +135.85%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.56
Upside: +372.56%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $332.68
Upside: +36.17%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $0.78
Upside: +349.64%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.75
Upside: +52.73%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.39
Upside: +308.16%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $73.71
Upside: +35.67%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $177.33
Upside: +135.72%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $13.54
Upside: +106.79%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.67
Upside: +474.37%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $9.38
Upside: +827.51%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.42
Upside: +933.06%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $10.05
Upside: +138.81%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $3.94
Upside: +128.43%